digital therapeutics
Digital technologies are cementing their place across healthcare, and the pharmaceutical sector is no exception.
A drug no longer needs to be a tangible object, according to panelist at the BIO 2018 convention in Boston.
Stakeholders across healthcare are beginning to weigh the benefits and challenges digital therapeutics could bring to their businesses, and pharma is no exception.
Today, Madison, Wisconsin-based digital respiratory health company Propeller Health announced a $20 million funding round led by a $10 million investment from Aptar Pharma.
San Francisco-based Hinge Health has completed a randomized control trial of its digital care program for chronic knee pain.
Although it hasn’t yet established its place as a mainstream treatment modality, virtual reality has grown from an interesting diversion into a frequent topic of conversation within digital health.
This morning, Boston-based Akili Interactive Labs announced the closure of a $55 million Series C funding round.
A small, 6-week retrospective study published in JMIR mHealth and uHealth found that a behavior health-focused videogame developed by digital health company Litesprite improved self-reported measures of depression, anxiety, and confidence in coping skills.
Digital therapeutics may be up and coming, but they also have a long way to go before their mainstream treatment options, according to experts who spoke at the digital therapeutics deep dive at HIMSS18.
From syringes to workflow management systems, healthcare is no stranger to adopting new technologies into standard care.